PORTLAND, Ore., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Jetblack Corp. (OTC: JTBK) (“The Company” “JTBK”) today announced more in depth details on their “first of its kind” wellness product in formulation. As a background, the recent identification of cannabinoid receptors, CB1 and CB2 receptors and their endogenous lipid ligands has started an exponential growth of studies exploring the endocannabinoid system and its regulatory functions concerning health and disease.
In the past decade, the endocannabinoid system has been implicated in a vast number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, regulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a vast range of disparate diseases and pathological conditions.
Jetblack Corp. has been formulating a product which helps flush or cleanse the endocannabinoid system and CB1 and CB2 receptors to make marijuana and its cannabinoids more effective. The more a person smokes or ingests marijuana, there becomes a diminishing rate of effectiveness compared to an individual who consumes cannabis less regularly. If an individual is a regular consumer of marijuana, the effects are much milder and less effective than someone who ingests less regularly. Often heavy users complain about never getting “high”, barely feeling anything, or needing concentrates to get the desired effects. At a certain point for the regular user, even the concentrates will have little effect. In comparison, a user who consumes cannabis less regularly will feel much greater effects of the cannabis once consumed.
According to New Frontier Data, statistics in 2017 have shown roughly 12% of the adult population in the US consume marijuana daily, while 11% of the adult population uses it weekly. In 2018, overall sales of legal marijuana in the US was greater than 9 billion dollars.
JTBK’s product helps flush the endocannabinoid system and receptors so that a regular user can use less marijuana and be acutely more effective for the goals they would like to achieve. Potentially this will save the consumer money by using less marijuana products, have greater effectiveness for their desired effect, along with less unwanted side effects that marijuana gives by consuming less cannabis. A marijuana medical patient may also benefit greatly from this product by making the marijuana much more effective for relief of their conditions.
For someone looking to stop consuming cannabis for whatever reason, this product may also help to clear your system for “weaning off” of the cannabis. Sometimes heavy users will have some unwanted side effects from suddenly stopping consumption. Some individuals may suffer a loss of appetite from suddenly stopping consumption. Along with, irritability and a restless sleep to name a few. Often a regular user who stops consumption for 2 weeks may still have up to 500 nanograms or more in their system. Sometimes a regular user will need up to 60 days to clear their system completely. Our product may help clean out the system much faster, which will give less side effects to the individual in the “weaning” process.
The endocannabiniod system is still being studied, and research is in its infancy. The company believes this product may also benefit non-cannabis users as well, as we know now the endocannabinoid system plays an important role in our health. “This is why we have stated this is a wellness product from the beginning. We are looking forward to put the final touches on the formulation, begin test trials, along with manufacturing and production.” explained the CEO of Jetblack Corp. Daniel A. Goldin.
More information about Jetblack Corp. can be found at its website: www.Jetblackcorp.com and its twitter handle @jetblackcorp
Information regarding investments or financing may be directed to 1-888-611-5825 by leaving a detailed message or by sending an email to: firstname.lastname@example.org
This press release contains forward-looking statements. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward- looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties include market risks associated with our business, the inability to raise enough capital to complete our business, economic conditions and increasing competition. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The loss of key employees would be detrimental to the company success. Currently the company is considered a penny stock, which means the spreads can be very far apart, sometimes illiquid, and investors may not be able to sell when they want or for the price paid. In some circumstances the investor may lose all their investment.